Interleukin-2 targeted fusion toxin using parts of the diphtheria toxin data

SRGN (Hopkinton, Mass.) and collaborators published early results of an ongoing Phase I/II trial showing a marked response

Read the full 185 word article

How to gain access

Continue reading with a
two-week free trial.